Diabetes and Cardiovascular Risk: New Thinking, New Opportunities

Diabetes and Cardiovascular Risk: New Thinking, New Opportunities

Dr. Leahy joins Dr. Russell to discuss new therapeutic developments for diabetes based on cardiovascular risk.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Diabetes is a major global health emergency, affecting approximately 415 million adults and contributing to five million deaths each year. Cardiovascular disease is a serious complication of type 2 diabetes mellitus (T2DM), contributing to the majority of morbidity and mortality in this population.  In recent years, the cardiovascular impact of anti-diabetes medications has become the focus of research.  Recent findings from long-term, large-scale, cardiovascular outcome trials of antihyperglycemic agents have shown that some T2DM treatments can provide cardiometabolic benefits beyond glycemic control and may open the door for more successful management. 

    As a value added-resource, a specialized toolkit will also be included as a supplement to the webcast. The toolkit will provide reference materials including key publications for a deeper review of the data for clinicians as well as helpful information and resources for families and caregivers.

  • Learning Objectives

    • Describe the interrelationship between diabetes and cardiovascular risk;
    • Identify antidiabetes medications that can optimize glycemic control and minimize the adverse effects on cardiovascular disease;
    • Evaluate the efficacy and safety data of recent trials that examined the cardiovascular impact of antidiabetes pharmacotherapies;
    • Facilitate adaptation of collaborative care models and communication strategies to facilitate education of patients on diabetes and cardiovascular risk to optimize outcomes.
  • Target Audience

    The intended audiences for this activity are physicians and other health care professionals who manage patients with T2DM and cardiovascular risk.

  • Faculty & Disclosures

    Faculty: 
    John (Jack) L. Leahy, MD
    Professor of Medicine
    Sarah Nichols Gruenig Green & Gold Professor of Diabetes Research, 
    Co-Chief, Division of Endocrinology, Diabetes, and Metabolism
    University of Vermont College of Medicine
    Burlington, Vermont

    Host: 
    John Russell, MD
    Director, Family Medicine Residency Program
    Abington Jefferson Hospital
    Abington, Pennsylvania

    According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University Of Cincinnati College Of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

    The following faculty has reported real or apparent conflicts of interest that have been resolved:

    John (Jack) Leahy, MD, has disclosed the following relevant financial relationships: Served as an advisor board member for Janssen, Merck, Novo Nordisk, Sanofi and Valeritas.

    John Russell, MD (Host) has nothing to disclose.

    The following reviewers/planners/authors have reported real or apparent conflicts of interest:

    • Susan Tyler, MEd, CMP, CHCP, CME Director, has nothing to disclose.
    • Bruce Gebhardt, MD, CME Reviewer, has nothing to disclose.
    • Jennifer Holzberger, Program Coordinator, has nothing to disclose.
    • Otto Ratz, MD, has nothing to disclose.
    • Christina Culbert, MSc, has nothing to disclose.
  • Accreditation and Credit Designation Statements

    This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation

    University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.

  • Commercial Support

    This CME activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or CORE Medical Education, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Instruction for Participation

    There are no fees for participating in and receiving CME credit for this online activity. During the period of February 28, 2018 to February 27, 2019, participants must 1) read the CME information, including the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score of 70% and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post test and evaluation will have a statement of credit made available immediately.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Prova Education newsletters.

Better education for a better you.

* Required
Optional